We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Relsys International, the leading provider of software solutions for adverse event reporting, pharmacovigilance and risk management for the pharmaceutical industry, announced today that its flagship product, Argus Safety Web has been deployed by The Grunenthal Group, a leading German pharmaceutical company.
Israeli drugmaker Teva's Mitoxantrone hydrochloride injection, the company's generic treatment for prostate cancer, has been approved by the U.S. FDA, the company reported.
Canada-based YM BioSciences, a cancer product development company, has entered into an agreement to acquire Eximias Pharmaceutical, headquartered in Pennsylvania.
Japanese drugmaker Astellas has reported that its EU subsidiary has submitted a marketing authorization application for the candin antifungal agent micafungin for the treatment of systemic fungal infections to the European Medicines Agency (EMEA).
Japan-based drug companies Dainippon Sumitomo Pharma and Eisai have signed a licensing agreement to market Gasmotin, a gastroprokinetic agent, in 10 Asian countries, including Indonesia, Thailand and the Philippines.
Schering-Plough has revealed that it is to further develop a compound for the treatment of respiratory disease identified in the company's collaboration with Pharmacopeia.